Denmark: A study published in Cardiovascular Diabetology has found that patients with overweight or obesity who have prediabetes after a myocardial infarction face a substantially higher risk ...

Indian pharmaceutical giant Dr Reddy’s Laboratories is gearing up to introduce a generic and significantly cheaper version of Novo Nordisk’s blockbuster weight-loss drug Wegovy. The company’s move ...

Dr Reddy's Laboratories is set to launch a generic version of semaglutide in India on March 21. The company plans to offer both oral and injectable formats at competitive prices. This move aims to ...

The online pharmacy is collaborating with a digital health provider to combine direct-to-patient GLP-1 dispensing with virtual clinical support, highlighting evolving supply chain and regulatory ...

The AACE consensus statement emphasizes improvement of overall health in addition to weight reduction among adults with obesity and adiposity-based chronic disease.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

Dr Reddy’s Laboratories plans to introduce a generic version of Wegovy in India at a significantly reduced price. With the ...

Lowering the annual cost of semaglutide by 18% or making the current cash price available to all patients would make it cost-effective.

Find out more about how tirzepatide performed better than semaglutide in weight reduction in a 2026 network meta-analysis.

Doctors are recommending these three peptides as possible solutions to a number of longevity issues — from cell rejuvenation to metabolic health and risk of heart disease.

Operator: Good morning, ladies and gentlemen, and welcome to Veru Inc. Investors Conference Call. All participants will be in listen-only mode. Please note this event is being recorded.